

6th Annual Update on Liver Disease Saturday, October 8, 2022

PURPOSE AND CONTENT

This live CME activity is intended to update providers on a diverse range of topics including viral hepatitis, autoimmune liver disease, alcohol and nonalcoholic fatty liver disease, cirrhosis, portal hypertension, primary liver cancer and liver transplantation. The conference will focus on recent advances, publications and expert opinions. In addition to didactic lectures, case presentations will be included to make the activity interactive and practical.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, participants should be able to:

- Analyze indications and interpretation of viral hepatitis testing and identify those patients who would benefit from antiviral therapy.
- Implement appropriate management and identify potential therapies for hepatic steatohepatitis.
- Examine the complications of ascites, hepatorenal syndrome, variceal hemorrhage and encephalopathy and treatment options.
- Determine the diagnosis and treatment of liver masses including hepatocellular carcinoma and cholangiocarcinoma.
- Identify the indications for liver transplantation and learn about recent advancements in the field and policies changes regarding organ allocation.

EDUCATIONAL METHODS

Didactic lectures, Patient Case Reviews, Discussion Panels, and Interactive Q&A Sessions

TARGET AUDIENCE

This CME activity is designed for physicians, nurse practitioners, physician assistants, and specialists in Internal Medicine and Gastroenterology caring for liver diseases.

HOW TO ACCESS CONFERENCE RESOURCES

IN-PERSON ATTENDEES:

Go to conference website: <https://cme.utsouthwestern.edu/rp2210b>

CLICK ON "PROGRAM" TAB TO ACCESS: CME Handout and Presentation Slides

VIRTUAL ATTENDEES:

Go to Whova conference app site: https://whova.com/portal/webapp/utswe3_202202/

LOCATE LEFT PANEL – use these tabs to access:

"**Home**" - general conference information, CME Handout, livestream via Zoom.

"**Agenda**" – list of individual presentation. Click "View Session" for presentation details.

"**Attendees**" - view list of conference speakers and virtual attendees.

"**Exhibitors**" - visit the virtual Exhibit Hall.

ACCREDITATION

The University of Texas Southwestern Medical Center at Dallas is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians

The University of Texas Southwestern Medical Center designates this live activity for a maximum of 6.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Non-Physicians

The University of Texas Southwestern Medical Center certifies that non-physicians will receive an attendance certificate stating that they participated in the activity that was designated for 6.0 AMA PRA Category 1 Credit[™].

ABIM MAINTENANCE OF CERTIFICATION (MOC)



Successful completion of this CME activity enables the participant to earn up to 6.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points

EVALUATIONS AND CERTIFICATES

Attendees will receive an email with a link to access the evaluation. Once the evaluation is completed, you will be able to claim your credit and print out your CME certificate. This evaluation is an important tool for assessing the effectiveness of this activity as well as for planning future activities.

PRESENTATIONS

Final presentations are posted on the course webpage: <https://cme.utsouthwestern.edu/rp2210b> (click on the PROGRAM tab).

DISCLAIMER

This symposium has been planned to be well-balanced and objective in discussion of comparative treatment regimens, and the symposium format allows for the free scientific exchange of ideas. Information and opinions offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information.

DISCLOSURE OF UNLABELED USES

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product, or consult the Physicians' Desk Reference.

CONFERENCE FACULTY

COURSE DIRECTORS

Amit Singal, M.D.

Professor, Department of Internal Medicine
Medical Director, Liver Tumor Program
Clinical Chief of Hepatology
UT Southwestern Medical Center

Shannan Tujios, M.D.

Assistant Professor, Department of Internal Medicine
Program Director, Transplant Hepatology Fellowship Program
UT Southwestern Medical Center

UT SOUTHWESTERN SPEAKERS

Jaime Almandoz, MD

Associate Professor, Internal Medicine
Assistant Medical Director, UTSW Clinical
Research Unit in the Center for Translational
Medicine

Maria del Pilar Bayona Molano, MD

Associate Professor, Radiology

Thomas Cotter, MD

Assistant Professor, Internal Medicine

Lafaine Grant, MD

Associate Professor, Internal Medicine

David Hsieh, MD

Assistant Professor, Internal Medicine

Thomas Kerr, MD, PhD

Associate Professor, Internal Medicine

Maddie Kubiliun, MD, MPH

Assistant Professor, Internal Medicine

William Lee, MD

Professor, Internal Medicine

Maria (Rita) Lepe-Suastegui, MD

Assistant Professor, Department of Internal
Medicine

Marlyn Mayo, MD

Professor, Department of Internal Medicine

Arjmand Mufti, MD

Associate Professor, Internal Medicine
Medical Director of Liver Transplantation and
Living Liver Transplantation
Fellowship Program Director for Digestive and
Liver Disease

Jacqueline O'Leary, MD, MPH

Associate Professor, Internal Medicine
Chief of Hepatology, Dallas VA Medical Center

Madhukar Patel, MD, MBA, ScM

Assistant Professor, Department of Surgery
Surgical Director, UTSW Living Donor Liver
Transplant Program

Mark Pedersen, MD

Assistant Professor, Internal Medicine

Lisa VanWagner, MD, MSc

Associate Professor, Internal Medicine

DISCLOSURE OF FINANCIAL RELATIONSHIPS WITH INELIGIBLE COMPANIES

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), The University of Texas Southwestern Medical Center, Office of Continuing Medical Education (UTSW CME) requires that the content of CME activities and related materials provide balance, independence, objectivity, and scientific rigor. Planning must be free of the influence or control of any ineligible company, and promote improvements or quality in healthcare. In accordance with ACCME's Standards for Integrity and Independence in Accredited Continuing Education, all persons in the position to control the content of an education activity are required to disclose all financial relationships in any amount occurring within the past 24 months with any ineligible company producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. UT Southwestern also considers ineligible those companies producing, marketing, selling, re-selling, or distributing healthcare products in development for future use on patients, such as healthcare product research companies. All reported financial relationships with ineligible companies are reviewed for relevancy and then mitigated through a content review process prior to the activity (where applicable).

The following is a listing of all individuals that contributed to the educational content of this activity and reported having the following financial relationships within the last 24 months:

Name	Financial Relationship Disclosed
Jaime Almandoz, M.D.	<u>Independent Contractor:</u> Eli Lilly and Co – Obesity; Novo Nordisk – Obesity
Thomas Kerr, M.D	<u>Independent Contractor:</u> UpToDate, Alexion <u>Grant or Contracts:</u> Alexion
William Lee, M.D.	<u>Grant or Contract:</u> Merck - Hepatitis C; Intercept - Fatty Liver Disease; Conatus - Fatty Liver Disease IL - pharma research; Alexion - pharma research; Eiger - pharma research Gilead - fatty liver clinical trial; Novo Nordisk - fatty liver clinical trial <u>Independent Contractor:</u> Genentech - Consultant (drug toxicity); Forma Pharmaceuticals - Consultant (drug toxicity); Seattle Genetics - Consultant (drug toxicity); Karuna - Consultant (drug toxicity); Cortexyme - Consultant (drug toxicity)
Marlyn Mayo, M.D.	<u>Grant or Contract:</u> Intercept – NASH; Mirum - PSC Cymabay – PBC; Target – PBC; GlaxoSmithKline – PBC; Genfit - PBC Mallinckrodt – HE; Salix - HE <u>Professional Services:</u> Target – PBC; Glaxo Smith Kline – PBC; Cymabay - PBC
Jacqueline O’Leary, M.D.	<u>Professional Services</u> Abbvie – HCV; Gilead – HCV; Genfit - ACLF
Amit Singal, M.D.	<u>Independent Contractor</u> Bayer, Eisai, Exelixis, Genentech, Roche, Glycotest, Exact Sciences, GRAIL, Wako Diagnostics, AstraZeneca
Lisa VanWagner, M.D.	<u>Grant Or Contract</u> W.L. Gore & Associates (TIPS); Intercept Pharmaceuticals (OCA for NASH) <u>Professional Services</u> Mercaldo Law Firm (Expert Witness services) <u>Independent contractor</u> Noble Insights (NASH therapeutics); Gerson Lehrman Group (NASH) <u>Professional Services</u> Hamilton Law Firm (Expert Witness); Wapner Newman Law Firm (Expert Witness)

DISCLOSURES (continued from previous page)

The following is a listing of all individuals that contributed to the educational content of this activity and reported having no financial relationships within the last 24 months:

Speakers

Maria del Pilar Bayona Milano, M.D.
Thomas Cotter, M.D., M.S.
Lafaine Grant, M.D.
David Hsieh, M.D.
Maddie Kubiliun, M.D.
Maria (Rita) Lepe-Suastegui, M.D.
Arjmand Mufti, M.D.
Madhukar Patel, M.D.
Mark Pedersen, M.D.

Course Director

Shannan Tujios, M.D.

CME Coordinator

Mark Vinciguerra (CME Staff)

ACKNOWLEDGMENTS

Exhibits

The University of Texas Southwestern Medical Center gratefully acknowledges the following companies exhibiting at today's conference:

GOLD LEVEL

Exelixis
Genentech
Gilead

SILVER LEVEL

Eisai
Exact Sciences Corporation
Glycotest

BRONZE LEVEL

Abbvie
Alexion Pharmaceuticals, Inc.
Bayer
Cook Medical
Fujifilm Healthcare America
Helioliver
Intercept Pharmaceutical
Salix Pharmaceutical
Werfen USA, LLC

6th Annual Update on Liver Disease Saturday, October 8, 2022

AGENDA

7:15 a.m.	Registration, Breakfast and Exhibits	
8:00-8:10	Welcome and Announcements	
8:10-8:35	Viral Hepatitis A-E	Dr. William Lee
8:35-8:55	AIH/PBC/PSC: Difficult Patients Cases	Dr. Marlyn Mayo
9:00-9:20	Emerging Topics in NAFLD	Dr. Maddie Kubiliun
9:25-9:55	Nutrition and Pharmacology for NASH	Dr. Jaime Almandoz
10:00-10:20	Questions & Answers	Panel
10:20-10:40	Break	
10:45-11:05	Non-invasive Markers and Portal HTN	Dr. Lafaine Grant
11:10-11:30	Acute on Chronic Liver Failure	Dr. Jacqueline O’Leary
11:35-12:15	Challenging Patient Cases (Expert panel: Drs. Rita Lepe, Thomas Kerr, and Lisa VanWagner)	Dr. Shannan Tujios
12:15-12:30	Questions & Answers	Panel
12:30-1:00	Lunch and Exhibits	
1:00-1:20	Alcohol Associated Liver Disease	Dr. Thomas Cotter
1:25-1:45	Indications for Liver Transplant	Dr. Mark Pedersen
1:50-2:10	Update in Liver Transplant	Dr. Arjmand Mufti
2:15-2:30	Advances in Treatment of HCC	Dr. Amit Singal
2:35-3:15	Patient Cases: Liver Masses (Expert panel: Drs. Madhukar Patel, Maria del Pilar Bayona Molano, and David Hsieh)	Dr. Amit Singal
3:20-3:40	Questions & Answers	Panel
3:45 p.m.	Closing Remarks & Adjourn	

NOTES

